ANDRES MANUEL R
CERVANTES RUIPEREZ
CATEDRÁTICO/A DE UNIVERSIDAD
Hospital del Mar
Barcelona, EspañaPublicaciones en colaboración con investigadores/as de Hospital del Mar (21)
2024
-
Pharmacokinetics (PK) of Tiragolumab in First-in-Human Study in Patients with Mixed Solid Tumors (GO30103)
Journal of Clinical Pharmacology, Vol. 64, Núm. 5, pp. 544-554
2023
-
Long-term platinum-based drug accumulation in cancer-associated fibroblasts promotes colorectal cancer progression and resistance to therapy
Nature communications, Vol. 14, Núm. 1, pp. 746
-
The prognostic potential of CDX2 in colorectal cancer: Harmonizing biology and clinical practice
Cancer Treatment Reviews, Vol. 121
2022
-
In the literature: December 2021
ESMO Open
2021
-
Trends and outcome of neoadjuvant treatment for rectal cancer: A retrospective analysis and critical assessment of a 10-year prospective national registry on behalf of the Spanish Rectal Cancer Project
European Journal of Surgical Oncology, Vol. 47, Núm. 2, pp. 276-284
2020
-
Detection of postoperative plasma circulating tumour DNA and lack of CDX2 expression as markers of recurrence in patients with localised colon cancer
ESMO Open, Vol. 5, Núm. 5
-
The McCAVE Trial: Vanucizumab plus mFOLFOX-6 Versus Bevacizumab plus mFOLFOX-6 in Patients with Previously Untreated Metastatic Colorectal Carcinoma (mCRC)
Oncologist, Vol. 25, Núm. 3, pp. e451-e459
2019
2018
-
A multi-omic analysis for prospective patient stratification in localised colorectal cancer (CRC)
Annals of oncology : official journal of the European Society for Medical Oncology, Vol. 29, pp. viii717
-
Phase Ib study evaluating safety and clinical activity of the anti-HER3 antibody lumretuzumab combined with the anti-HER2 antibody pertuzumab and paclitaxel in HER3-positive, HER2-low metastatic breast cancer
Investigational New Drugs, Vol. 36, Núm. 5, pp. 848-859
2017
-
Phase Ib study of lumretuzumab plus cetuximab or erlotinib in solid tumor patients and evaluation of HER3 and heregulin as potential biomarkers of clinical activity
Clinical Cancer Research, Vol. 23, Núm. 18, pp. 5406-5415
-
Prospective validation of a lymphocyte infiltration prognostic test in stage III colon cancer patients treated with adjuvant FOLFOX
European Journal of Cancer, Vol. 82, pp. 16-24
2016
-
First-in-human phase i study of lumretuzumab, a glycoengineered humanized anti-HER3 monoclonal antibody, in patients with metastatic or advanced HER3-positive solid tumors
Clinical Cancer Research, Vol. 22, Núm. 4, pp. 877-885
2015
-
FCGR polymorphisms and cetuximab efficacy in chemorefractory metastatic colorectal cancer: An international consortium study
Gut, Vol. 64, Núm. 6, pp. 921-928
2012
-
First-Line XELOX plus bevacizumab followed by XELOX plus bevacizumab or single-agent bevacizumab as maintenance therapy in patients with metastatic colorectal cancer: The phase III MACRO TTD study
Onkologie, Vol. 6, Núm. 2, pp. 96-103
-
First-line XELOX plus bevacizumab followed by XELOX plus bevacizumab or single-agent bevacizumab as maintenance therapy in patients with metastatic colorectal cancer: The phase III MACRO TTD study
Oncologist, Vol. 17, Núm. 1, pp. 15-25
-
Role of Kras Status in Patients with Metastatic Colorectal Cancer Receiving First-Line Chemotherapy plus Bevacizumab: A TTD Group Cooperative Study
PLoS ONE, Vol. 7, Núm. 10
2006
-
A Phase II study of preoperative radiotherapy and concomitant weekly irinotecan in combination with protracted venous infusion 5-fluorouracil, for resectable locally advanced rectal cancer
International Journal of Radiation Oncology Biology Physics, Vol. 66, Núm. 1, pp. 201-205
2003
-
Irinotecan (CPT-11) in Metastatic Colorectal Cancer Patients Resistant to 5-Fluorouracil (5-FU): A Phase II Study
Methods and Findings in Experimental and Clinical Pharmacology, Vol. 25, Núm. 8, pp. 639-643
2000
-
Two consecutive studies using oral UFT-based chemotherapy regimens in elderly patients with advanced colorectal cancer
Clinical and Translational Oncology, Vol. 2, Núm. 3, pp. 154-158